Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement.
Across FY2015–FY2019: $5.97M in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Also on August 12, 2024, the Company issued $50.0 million in aggregate principal amount of the Company’s 4.75% Convertible Senior Notes due February 15, 2030 (the “Notes”) pursuant to the previously announced Purchase Agreement (the “Purchase Agreement”), dated August 5, 2024, by and between the Company and Braidwell Transaction Holdings LLC – Series 10 (the “Purchaser”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of August 12, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). The Indenture and form of Notes are also filed as Exhibits 4.1 and 4.2 hereto, and are incorporated herein by reference.
Issuer evidence: On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
Supporting evidence: Also on August 12, 2024, the Company issued $50.0 million in aggregate principal amount of the Company’s 4.75% Convertible Senior Notes due February 15, 2030 (the “Notes”) pursuant to the previously announced Purchase Agreement (the “Purchase Agreement”), dated August 5, 2024, by and between the Company and Braidwell Transaction Holdings LLC – Series 10 (the “Purchaser”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of August 12, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). The Indenture and form of Notes are also filed as Exhibits 4.1 and 4.2 hereto, and are incorporated herein by reference.
Term Loan Agreement
TermLoan · OrthoPediatrics Corp.
Reference: Term Loan Agreement
Active
Outstanding
—
Commitment
—
Availability
—
Maturity
—
Reported commitment:USD 25,000,000Reported 2024-08-12Disclosed facility capacity; the amount drawn and capacity available today are not established.
Covenant terms for this agreement are not yet verified.
On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
Issuer evidence: On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
Supporting evidence: On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.35×
Peer median 3.14×
EV/EBIT
—
Peer median 23.15×
P/E (TTM)
—
Peer median 27.38×
Price/Sales (TTM)
3.14×
Peer median 3.02×
Price/Book
2.44×
Peer median 3.57×
EV/Adj. EBITDA (FY2025)
60.01×
Peer median 11.27×
Peer medians compare against the 65 similar-size Medical Devices companies (of 164 listed).
EV/Adj. EBITDA uses
the company-stated
“Adjusted EBITDA”,
extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses
the company-stated
“Adjusted EBITDA”,
extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.